Bristol-Myers Squibb Company (BMY)
| Market Cap | 121.73B +31.6% |
| Revenue (ttm) | 49.19B +3.1% |
| Net Income | 9.28B +83.8% |
| EPS | 4.54 +82.7% |
| Shares Out | 2.04B |
| PE Ratio | 13.12 |
| Forward PE | 9.27 |
| Dividend | $2.52 (4.23%) |
| Ex-Dividend Date | Oct 2, 2026 |
| Volume | 9,885,750 |
| Open | 58.94 |
| Previous Close | 58.81 |
| Day's Range | 58.64 - 59.60 |
| 52-Week Range | 42.52 - 68.64 |
| Beta | 0.18 |
| Analysts | Hold |
| Price Target | 66.13 (+10.98%) |
| Earnings Date | Oct 29, 2026 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for BMY stock is "Hold." The 12-month stock price target is $66.13, which is an increase of 10.98% from the latest price.
News
Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement.
U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb's CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CAMZYOS--U.S. FDA Approves Expanded Indication for BMS's CAMZYOS for the Treatment of Symptomatic oHCM in Adults and Pediatric Patients.
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #IMS26--BMS Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial.
Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026.
Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CCRWest2026--Bristol Myers Squibb Presents Sotyktu Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years.
Bristol Myers Squibb Announces Dividend
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.
Bristol Myers' blood cancer cell therapy meets main goal in mid-stage trial
Bristol Myers Squibb said on Tuesday its experimental cell therapy for a type of blood cancer had met the main goal of a mid-stage trial.
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CARTCellTherapy--Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial.
Drugmakers quietly halted autoimmune drug trials because of deaths or problematic side effects, raising questions about disclosure around experimental research
Trial freezes by Novartis and Bristol Myers have triggered a race to understand why a promising autoimmune treatment turned risky.
Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services
Technical indicators have turned bullish for the three stocks.
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten).
Bristol Myers ends blood cancer drug deal with cell therapy maker Cellares
Bristol Myers Squibb has ended its partnership with cell therapy startup Cellares to expand the manufacturing of its personalized blood cancer therapy, a company spokesperson told Reuters on Tuesday...
Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery
SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery.
The Key to Pharma M&A: Never Shopping Hungry
Pharmaceutical chiefs are always hunting for drugs to replace expiring blockbusters. But shopping while hungry can lead to expensive mistakes.
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CELMoD--U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS.
US FDA approves Bristol Myers' blood cancer treatment
The U.S. FDA on Thursday approved Bristol Myers Squibb's combination treatment for patients with a rare form of blood cancer whose illness had relapsed or not responded to other treatments, the he...
Lawsuit against Bristol Myers over delayed cancer drug is revived
A U.S. federal appeals court said a judge erred in dismissing a $6.7 billion lawsuit accusing Bristol Myers Squibb of cheating former Celgene shareholders by delaying federal approval for three drugs...
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutic...
Bristol Myers to build $2.3 billion manufacturing site in Houston
Drugmaker Bristol Myers Squibb on Monday said it will spend about $2.3 billion to build a new manufacturing facility in Houston, Texas, part of a previously announced $40 billion commitment to inves...
Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas.
Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery
NEW YORK--(BUSINESS WIRE)-- #AgenticAI--Schrödinger, Inc. announced a strategic agreement with BMS to deploy Bunsen, Schrödinger's agentic AI co-scientist, within its research organization.
'No discussions' over AstraZeneca-Bristol Myers deal, senior source says
There are "no discussions" ongoing between AstraZeneca and Bristol Myers Squibb over a potential deal, a senior source close to the matter told Reuters on Wednesday, quashing the prospect of a moot...
More Biotech M&A Is on the Way, Whether an AstraZeneca-Bristol Myers Deal Happens or Not
Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.